2018
DOI: 10.1080/13543776.2018.1530217
|View full text |Cite
|
Sign up to set email alerts
|

Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
2
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(14 citation statements)
references
References 37 publications
0
14
0
Order By: Relevance
“…It also seems reasonable to assume that TLR6 becomes activated during infection by the V. alginolyticus △ vscC strain. In mammalian cells, since activation of TLRs serves to promote innate responses and initiate adaptive immunity ( 82 , 83 ), such features are of interest because these pathways can be exploited as potential vaccine adjuvants ( 84 , 85 ). TLR6 is located on the plasma membranes, recognizing extracellular microbial pathogenic molecules with distinct PAMPs and inducing inflammation through MyD88- and TRAF6-mediated activation of NF-κB in human ( 86 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It also seems reasonable to assume that TLR6 becomes activated during infection by the V. alginolyticus △ vscC strain. In mammalian cells, since activation of TLRs serves to promote innate responses and initiate adaptive immunity ( 82 , 83 ), such features are of interest because these pathways can be exploited as potential vaccine adjuvants ( 84 , 85 ). TLR6 is located on the plasma membranes, recognizing extracellular microbial pathogenic molecules with distinct PAMPs and inducing inflammation through MyD88- and TRAF6-mediated activation of NF-κB in human ( 86 ).…”
Section: Discussionmentioning
confidence: 99%
“…immunity (82,83), such features are of interest because these pathways can be exploited as potential vaccine adjuvants (84,85). TLR6 is located on the plasma membranes, recognizing extracellular microbial pathogenic molecules with distinct PAMPs and inducing inflammation through MyD88-and TRAF6-mediated activation of NF-kB in human (86).…”
Section: Discussionmentioning
confidence: 99%
“…In a major, highly recommended review article, Irvine and coworkers considered that biotechnology combined with the nanomaterials science could bring about safer and more efficient vaccine formulations with major roles for the nanoparticles (NPs) [ 116 ]. In a fast moving field encompassing cancer nanotechnology [ 50 , 89 , 90 , 95 , 117 ], vaccinology against pathogenic viruses [ 61 , 62 , 96 , 97 , 98 , 99 , 100 , 106 , 118 ], and microbes such as bacteria [ 19 , 108 , 112 , 119 , 120 ], fungi [ 119 ], and parasites [ 22 , 120 , 121 , 122 , 123 , 124 ], elegant nanomaterials that are difficult to scale up for commercialization cannot become useful in clinics [ 116 , 125 ].…”
Section: Nanoparticlesmentioning
confidence: 99%
“…Against malaria, adjuvants have to induce both antibodies and helper T cells; non-inflammatory polystyrene nanoparticles (PS NPs) as adjuvants and a protein conserved across several Plasmodium species named MSP4/5 as antigen, Th1 and Th2 immune responses was obtained; there was 50–80% protection against blood-stage malaria linked to interferon–gamma production [ 120 ]. Currently, no efficient vaccine against malaria in clinics is available; efforts to develop malaria vaccines have been reviewed [ 121 , 122 , 123 ]. Both discovery of better immunostimulatory formulations and adjuvants are needed.…”
Section: Nanoparticlesmentioning
confidence: 99%
“…Flagellin ( iC) inherently attaches to toll-like receptor 5 (TLR5) as a natural agonist. FliC protein is a highly conserved bacterial protein; it can stimulate the humoral and cellular immune system by producing antibodies, cytokines, and interleukins that prevent the parasite entry in the pre-erythrocytic stage of malaria [23][24][25]. Therefore, the present study aimed to design a multi-epitope vaccine by utilizing bioinformatics methods based on PfGARP epitopes to elicit a humoral immune response against blood-stage of malaria infection.…”
Section: Introductionmentioning
confidence: 99%